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The clinical eﬃcacy of sublingual immunotherapy (SLIT) with natural allergen extracts has been established in IgE-dependent
respiratory allergies to grass or tree pollens, as well as house dust mites. Sublingual vaccines have an excellent safety record,
documented with approximately 2 billion doses administered, as of today, in humans. The oral immune system comprises various
antigen-presenting cells, including Langerhans cells, as well as myeloid and plasmacytoid dendritic cells (DCs) with a distinct
localisation in the mucosa, along the lamina propria and in subepithelial tissues, respectively. In the absence of danger signals, all
these DC subsets are tolerogenic in that they support the diﬀerentiation of Th1- and IL10-producing regulatory CD4+ Tc e l l s .O ra l
tissues contain limited numbers of mast cells and eosinophils, mostly located in submucosal areas, thereby explaining the good
safety proﬁle of SLIT. Resident oral Th1, Th2, and Th17 CD4+ T cells are located along the lamina propria, likely representing
a defence mechanism against infectious pathogens. Second-generation sublingual vaccines are being developed, based upon re-
combinant allergens expressed in a native conformation, possibly formulated with Th1/T reg adjuvants and/or mucoadhesive
particulate vector systems speciﬁcally designed to target oral dendritic cells.
1.Introduction
Following the pioneer studies by Noon and Freeman [1, 2]
conducted a century ago, allergen-speciﬁc immunotherapy
is presently the only curative treatment for type I allergies.
Speciﬁcally, subcutaneous immunotherapy (SCIT) was
shown to provide clinical beneﬁt for patients with IgE-de-
pendent allergies to either grass, weed, and tree pollens, dust
mites (e.g., Dermatophagoides pteronyssinus, Dermatoph-
agoides farinae), cat and dog epithelia, or moulds [3, 4]. Also,
SCIT has become a reference treatment for venom allergies
[3]. Although SCIT has been occasionally performed with
soluble allergens, in most circumstances, subcutaneous vac-
cinesincludeadjuvantssuchasaluminumhydroxideorcalci-
um phosphate. Since SCIT requires multiple injections and
can be associated with severe side eﬀects, including anaphy-
lactic shocks, safer and noninvasive mucosal routes of ad-
ministration have been explored as an alternative [5, 6].
Most particularly, sublingual immunotherapy (SLIT)
was investigated in allergic patients almost twenty years ago
and is now established as a valid noninvasive alternative to
subcutaneous immunization to treat type I respiratory aller-
gies [5–8]. Although the sublingual route is the only mucos-
al route commonly used in humans for tolerance induction
in allergic patients, other exploratory routes are being tested,
including the oral, intranasal, epicutaneous and intralym-
phatic routes [9–20]( Table 1). This review focuses on the
clinical indications, mechanisms of action, and future devel-
opments pertaining to sublingual allergy vaccines.
2.SublingualAllergyVaccinesas
a New Therapeutic Class
Sublingualimmunotherapy(SLIT)representsaformofther-
apeutic vaccination aiming to a long-term allergen-speciﬁc
immunomodulation in patients with allergic rhinoconjuc-
tivitis, with or without moderate asthma [6]. It is performed
by reiterated administration (over months or even years)
of an allergen extract in the form of drops, fast dissolving2 Clinical and Developmental Immunology
Table 1: Compared characteristics of sublingual versus other administration routes for allergy vaccines.
Routes Current clinical indications Comments Ref
Sublingual (SLIT)
(i) Established as a safe and eﬃcacious treatment for
IgE-dependent respiratory allergies
(rhinoconjunctivitis with or without moderate
asthma)
(ii) For adults and 5–15 year old children
(i) No adjuvants
(ii) Dose 50 to 100 fold the one used for SCIT
(iii) Treatments available as drops, fast-dissolving
tablets, lyocs)
(iv) Two sublingual grass pollen tablets (Grazax,
Oralair) have been registered in Europe as
pharmaceutical specialties)
(v) Excellent safety record (mostly moderate local
reactions). Systemic reactions are extremely rare)
(vi) Eﬃcacy documented by large scale double blind
placebo controlled Phase III trials (evidence-based
medicine)
[5–8]
Subcutaneous
(i) Same as SLIT
(ii) Venom allergies
(iii) Latex allergies
(i) Adjuvants (aluminum salts or calcium
phosphate) are being used
(ii) For eﬀective immunotherapy, a 5 to 25μg
maintenance dose of allergen is necessary
(iii) Eﬃcacy documented by historical practice
(reference route since 1911)
(iv) Potential safety issues (besides acceptable local
reactions, risk of infrequent but life threatening
anaphylactic shocks).
[3, 4]
Exploratory routes
(oral, nasal,
epicutaneous,
intralymphatic)
(i) None as of today
(ii) Numerous clinical studies are being conducted
in patients with respiratory allergies (mites, pollens)
or food allergies (milk, egg, peanut)
(i) Encouraging results in small cohorts of patients
(ii) Safety and eﬃcacy remain to be conﬁrmed in
large scale clinical studies.
(iii) Expected positive outcomes of those new routes
include new applications for immunotherapy (e.g.,
food allergy for the oral or epicutaneous routes) or
tolerance induction with a limited number of
administrations (e.g., intralymphatic route)
[9–20]
tablets, or lyocs [6, 21]. Patients are asked to maintain the
allergen(s)underthetonguefor1-2mntoallowcontactwith
the oral mucosa. The allergens are subsequently swallowed,
as per the “sublingual-swallow” procedure. In all circum-
stances, high doses (usually 50- to 100-fold the ones used for
SCIT) of the allergen(s) are being used in the absence of any
adjuvant [6, 21]. Currently, sublingual vaccines are based on
aqueous extracts prepared from natural allergenic materials
such as animal hair, pollens, or lab cultures of house dust
mites [22]. Less frequently, these allergens are treated with
glutaraldehyde to form polymers precluding IgE reactivity,
but the clinical eﬃcacy of such “allergo¨ ıds” remains to be
documented [3, 4].
Multiple studies further compiled in metaanalyses have
demonstrated the eﬃcacy of sublingual drops in adult and
pediatric patients with allergic rhinoconjunctivitis to either
pollens (from common grasses, ragweed, parietaria, birch,
olive tree, cupressus), house dust mites, or cat dander [23–
27]. More speciﬁcally, SLIT signiﬁcantly reduces both rhino-
conjunctivitis symptoms as well as the need for symptomat-
ic medication. These studies, as well as the experience cumu-
lated by allergists during their daily practice (which together
account for around 2 billion doses of sublingual vaccines ad-
ministered to human beings), have unambiguously docu-
mented the excellent safety proﬁle of sublingual vaccines [6,
23–27]. Speciﬁcally, treatment-related adverse events include
frequent (i.e., in more that 60% of patients) but moderate
local reactions in the form of throat irritation, ear pruritus,
or tongue oedema [6]. Those adverse events are mostly ob-
served when SLIT is initiated, and are usually self resolving
without any speciﬁc further treatment. In contrast to SCIT,
systemic reactions, most particularly in the form of anaphy-
laxis, are extremely rare, and are thought to be linked to the
nonrespect of commonly accepted medical guidelines (i.e.,
administration of overdoses or inappropriate allergen mixes,
treatment of patients with uncontrolled asthma) [4, 6].
R e c e n t l y ,t w os u b l i n g u a lg r a s sp o l l e nt a b l e t sh a v eb e e n
developed and shownin multiple double-blind placebo-con-
trolled Phase III clinical studies conducted in both adults
and children to be highly eﬃcacious, with an overall 30–
40% improvement in rhinoconjonctivitis symptom scores
when compared with placebo [28, 29]. Another large-scale
study has also documented the clinical eﬃcacy of SLIT in
perennial allergy (i.e., to house dust mites) using a tablet
containing extracts from the two common D. pteronyssinus
and D. farinae mite species [30]. Other trials have demon-
strated a long-term eﬃcacy of sublingual immunotherapy,
for example, following a three-year administration of grass
pollen tablets [31, 32]. In addition, those allergic patients
remained protected for at least two years after stopping the
treatment, thus documenting a “disease-modifying” eﬀect
of SLIT. Based on those results, such sublingual tablets
have been registered as pharmaceutical specialties (Grazax,
Oralair) in Europe. The recommendation to use sublingualClinical and Developmental Immunology 3
immunotherapy has been endorsed by the World Health
Organisation (WHO) in several position papers on allergen
immunotherapy as well as by the allergic rhinitis and its
Impact on asthma (ARIA) workshop group [3, 4, 6].
3.SpeciﬁcProperties ofthe Oral
Immune System
The sublingual route has been initially used for small syn-
theticdrugs(e.g.,nitroglycerine,opioidanalgesics)forwhich
a fast plasmatic release was needed [21]. In contrast to such
small molecules, proteins do not cross the mucosa to reach
the bloodstream, but are rather captured by professional an-
tigen-presenting cells (APCs) within 15 to 30 minutes, which
will subsequently migrate to draining cervical submaxillary
l y m p hn o d e sw i t h i n1 2t o2 4h o u r s( Figure 1)[ 21, 33].
This makes the sublingual route very interesting for clinical
tolerance induction over other mucosal routes, including the
oralroute,inthattheantigenisbeingcapturedandprocessed
by APCs prior to signiﬁcant proteolytic degradation, thus
preserving the integrity of T and B cell epitope repertoires.
A detailed mapping of the oral immune system, most
particularly of antigen-presenting cells (APCs), has been
completed in mice [33, 34]. Speciﬁcally, three subsets of oral
dendritic cells (DCs) exhibiting a distinct tissue distribu-
tionhavebeenidentiﬁedincluding(i)Langerhanscells(LCs)
located in the mucosa itself, (ii) a predominant subpop-
ulation of myeloid DCs (MDCs) located along the lamina
propia, and (iii) plasmacytoid DCs (pDCs) found in submu-
cosal tissues (Figure 1)[ 33]. In humans, LCs have similarly
been described in the mucosa itself, whereas myeloid and
plasmacytoid DCs are less abundant [35–38]. Noteworthy,
all these DC subsets are thought to be tolerogenic, in that
they produce both IL-10 and IL-12 cytokines and thus, drive
the diﬀerentiation of na¨ ıve CD4+ T cells towards a Th1/T
Reg phenotype (Figure 1). Among those APCs, Langerhans
cellsandasubsetofmacrophage-likeCD11b+CD11c−APCs
are thought to be critical in capturing the antigen/allergen
[33, 35, 36, 39].
Only few proinﬂammatory cells (i.e., mast cells (MCs) or
eosinophils (Eos)) are found in oral tissues, and these cells
are mostly located in muscular tissues (Figure 1)[ 34, 38]. In
this context, most allergens are likely captured by tolerogenic
dendritic cells in the upper layers of oral tissues prior to
reaching proinﬂammatory mast cells, thus explaining the
excellent safety proﬁle of the sublingual route, with virtually
no risk of severe systemic reactions when compared with
the subcutaneous route [6, 21, 35]. Lastly, resident CD4+
T lymphocytes are abundant in oral tissues, located in the
vicinity of myeloid APCs along the lamina propria. These
cells comprise both suppressive as well as eﬀector T cells, in-
cluding Th1, Th2, and Th17 lymphocytes, likely involved
in defence against infectious pathogens. This explains why
the sublingual route is also currently considered to elicit ef-
fector immune responses against pathogenic viruses [40].
Nonetheless, in the absence of any danger signal, the default
response to an antigen administered via the sublingual route
is tolerance induction following the induction of Th1/T reg
CD4+ T cells [21, 35].
4.ImmuneChangesAssociatedwith
Sublingual Immunotherapy
Allergen-speciﬁc immunotherapy is known to reduce both
immediate- and late-phase allergen-induced symptoms, via
both humoral and cellular mechanisms [41–43]. Immune
mechanisms leading to clinical tolerance, described in more
details below, are thought to be associated with both subcu-
taneous and sublingual immunotherapy. Most particularly,
changes in the polarization of allergen-speciﬁc CD4+ T-cell
responses are considered to be central, in that variations
in the patterns of cytokines produced signiﬁcantly impact
antibody responses as well as recruitment and activation of
proinﬂammatory cells in target mucosae [21, 41–43].
4.1.AntibodyResponses. Afteraninitialrise,allergen-speciﬁc
sublingual immunotherapy induces a prolonged decrease
in seric IgE levels and prevents the seasonal increase in
IgEs associated with exposure to environmental allergens
[21, 41–43]. For example, pollen immunotherapy results in
the blunting of the seasonal upregulation of speciﬁc IgEs,
while eliciting allergen-speciﬁc IgG responses—mostly IgG1
and IgG4. Such IgG antibodies may act as “blocking” anti-
bodies by competing with IgEs for allergen binding, thereby
inhibiting IgE-mediated allergen presentation to T cells [44].
In addition, they can engage low-aﬃnity Fc receptors for
IgGs (CD32) known to down regulate mast cell and B cell
activation [45]. A speciﬁc property of SLIT, when compared
to SCIT, is further to elicit allergen-speciﬁc IgAs, both in
serum and mucosal secretions [43, 46, 47].
4.2. Proinﬂammatory Cells. A reduced recruitment and ac-
tivation of inﬂammatory cells in target mucosae has been
observed following allergen-speciﬁc immunotherapy [48–
50]. Speciﬁcally, successful SLIT has been associated with
ad e c r e a s ei nt h er e c r u i t m e n to fm a s tc e l l s( b o t ht r y p t a s e /
chymase+ or tryptase+ only), basophils, and eosinophils in
the skin, nose, eye, and bronchial mucosae [21, 43].
4.3. T-Cell Responses. Sublingual immunotherapy shifts al-
lergic-speciﬁc CD4+ T-cells responses from Th2 to Th1, with
the stimulation of IFNγ-producing T lymphocytes [21, 42,
43].Inaddition,SLITalsoinducesregulatoryT(TReg)cells,
thought to play a central role in inhibiting eﬀector mech-
anisms associated with allergic inﬂammation [51, 52]. T Reg
cells induced during immunotherapy are type 1 (Tr1) cells
producing high levels of IL-10 and/or transforming growth
factor-β (TGF-β), known to decrease IgE production and to
enhance IgG4 and IgA production, respectively [42, 43]. In
addition, both IL-10 and TGF-β lower the release of pro-
inﬂammatory mediators and inhibit the production of Th2
cytokines [42].
5. FutureDirections
5.1. Development of Sublingual Recombinant Allergy Vaccines.
There is, as of today, no recombinant allergy vaccine com-
mercially available. With the advent of molecular biology
and the use of recombinant DNA technology, the possibility4 Clinical and Developmental Immunology
Figure 1: Fate of the allergen following sublingual administration. Following sublingual immunization, substantial amounts of the allergen
bind to epithelial cells within minutes, then cross the mucosa between 15 and 30 minutes. The allergen is subsequently captured by dendritic
cells (likely by Langerhans cells (LCs) within the mucosa itself and myeloid dendritic cells (MDCs) along the lamina propria) and processed
assmallpeptidespresentedinassociationwithMHCclassIandclassIImolecules atthecellsurface.ThoseDCsloadedwithallergen-derived
peptides reach cervical lymph nodes within 12 to 24 hours, where they interact with naive CD4+ T cells to support the diﬀerenciation of Th1
and T Reg cells within two to ﬁve days. These CD4+ T cells subsequently migrate into the blood and back to mucosal tissues, resulting in
allergen tolerance with downregulation of preexisting Th2 responses.
of developing highly puriﬁed allergens for sublingual im-
munotherapy is raising considerable interest [22, 53]. Over
the last decade, genes encoding the most important allergens
have been cloned (cf., updated list at http://www.allergen
.org/) and for a number of them, expressed as recom-
binant proteins. Such recombinant allergens oﬀer the advan-
tage over natural extracts of being better characterized and
easier to produce in a consistent manner [22, 53].
Vaccines based on recombinant allergens are particularly
suitablewhenthenumberoftargetallergensislimited,which
is the case for birch (Betula verrucosa) pollen allergy [54].
Over 95% of patients allergic to birch pollen display IgE
reactivity to the Bet v 1 allergen and up to 60% of these
patients are sensitized to Bet v 1 only. A recombinant form
of Bet v 1 (isoform a) has been produced in Escherichia coli
and shown to be folded similarly to the native protein, with
a compact and stable structure and a well-preserved anti-Clinical and Developmental Immunology 5
genicity [54]. This rBet v 1 protein has been initially tested
in a Phase I/II clinical trial via the subcutaneous route (using
15ug/dose in association with Alum as an adjuvant). Under
those conditions, the rBetv 1 allergen alone was as eﬃcient
as the total birch pollen extract in alleviating patients’ symp-
toms during the pollen season [55]. Based on those results,
rBet v 1 has been administered without any adjuvant via the
sublingual route in a Phase II study and shown to decrease
signiﬁcantly rhinoconjunctivitis symptoms as well as the use
of symptomatic medications, in comparison to placebo [56].
One pending question regarding the use of recombinant
allergens for immunotherapy is whether IgE binding epi-
topes should be preserved in the molecule [53]. Hypoaller-
genic forms of recombinant allergens or peptide fragments
have been produced which do not induce degranulation of
IgE+mastcellsorbasophils,whilemaintainingtheircapacity
to elicit IgG and CD4+ T responses [53]. However, while
hypoallergens could in theory represent safer vaccines, there
is, as of today, no evidence of their clinical eﬃcacy. With
respect to the sublingual route, oral DCs have been shown
to express Fc receptors for IgEs, which thus can be used to
better address the allergen onto APCs [37]. Interestingly, in
the Phase II study described above, rBet v 1 administered
sublingually was well tolerated at doses up to 50ugs, besides
the expected local reactions commonly associated with SLIT
[56]. For those reasons combined, our working hypothesis
is that recombinant allergens to be used sublingually should
rather be produced in a wild-type (i.e., native) conformation
in order to mimick the natural allergen [21, 22].
5.2. Adjuvants and Vector Systems for Sublingual Vaccines.
N o v e la d j u v a n t sa n dv e c t o rs y s t e m sc o u l db ec o n s i d e r e dt o
further improve the eﬃcacy of sublingual allergy vaccines
[57]. Those immunopotentiators could as well allow to
reduce the dose of allergens or simplify immunization
schemes. Potential mucosal adjuvants which have been suc-
cessfullytestedinmurineSLITmodelstomodulateTcellpo-
larization include ligands for Toll-like receptors (TLRs) 2
(e.g., Pam3Cysk4) and 4 (i.e., synthetic lipid A analogs) [57–
59]. Such TLR ligands enhancing tolerance induction via
the sublingual route share in common a capacity to elicit
mixed Th1/T reg CD4+ T cell responses. In addition, dex-
amethasone + (1, 25) dihydroxyvitamin D3 as well as select-
ed strains of probiotics (i.e., lactobacilli, biﬁdobacteria) rep-
resents potential T reg adjuvants, since they are powerful
inducers of IL-10 production by immune cells. As such,
these compounds enhance SLIT eﬃcacy in murine models
of OVA-induced asthma [58–61]. In humans, the only adju-
vant which has been tested via the sublingual route is mono-
phosphoryl lipid A (MPL), a TLR4 ligand-inducing Th1
responses. Coadministration of MPL enhanced IgG respons-
estotheallergenwhenusinghighdosesofadjuvant[62].The
clinical relevance of this enhancement of speciﬁc antibody
responses remains to be established.
Mucosal vectors could also enhance SLIT eﬃcacy, for
example, by protecting the allergen(s) from degradation by
local proteases or by targeting the allergen to antigen-pre-
senting cells [57]. As an example, the genetically detoxiﬁed
adenylatecyclase(CyaA)fromBordetellapertussisconjugated
to OVA was shown to enhance tolerance induction via the
sublingual route in OVA-induced asthmatic mice, as a con-
sequence of a superior targeting of oral CD11b+ tolerogenic
myeloid DCs [39]. In addition, positively charged polymers
have been used to generate mucoadhesive particulate vectors
which can enhance allergen interaction with negatively
charged epithelial cells and as a consequence, contact dura-
tion with the mucosa. Formulations of allergens within a
particle increase allergen uptake by antigen-presenting cells
with a phagocytic activity [57]. For example, both nano-
particles made from polymerized maltodextrin [47]o r
chitosan-based microparticles [63] were found to enhance
in vitro and in vivo allergen capture by tolerogenic oral
DCs, thus resulting in a stronger tolerance induction via the
sublingual route in murine asthma models. To date, no vec-
tor system has been evaluated sublingually in humans.
5.3.NewClinicalIndications. Bothsubcutaneousandsublin-
gual immunotherapies of patients with rhinoconjunctivitis
appear to prevent subsequent sensitization and evolution
towards asthma [24, 25, 27, 64]. In addition, several studies
suggest a beneﬁt of SLIT in controlling asthma associated
with house dust mites [6, 65, 66]. Additional clinical trials
in adult and pediatric patient populations are needed to
further document a beneﬁt of SLIT in this indication.
Recently,SLIThasalsobeentestedsuccessfullyinseveralnew
clinicalindications,includingallergiestolatexandfood(e.g.,
peach, kiwi, hazelnut) [67–69]. These studies conducted
on small cohorts of patients provided encouraging results,
both in terms of safety and clinical eﬃcacy (e.g., increase in
amounts of food allergens tolerated by the patients). Simi-
larly,SLIThasbeenrecentlyshowntodecreaseatopicderma-
titis symptoms linked with mite exposure, in patients with
mild-to-moderate disease [70]. Such results need to be fur-
therconﬁrmedinthecontextoflarge-scale-doubleblindpla-
cebo-controlled studies.
6. Conclusions
Sublingual vaccines based on biological extracts are being
used as a safe and eﬃcacious treatment for type I respir-
atory allergies. To provide consistent pharmaceutical-grade
products despite the inherent variability associated with bio-
logical extracts, well-established standardisation procedures
and comprehensive proteomic characterization methods are
being used to guarantee the quality of allergen extracts and
the robustness of manufacturing processes. Those improve-
ments have been recognised by regulatory authorities with
the registration in 2008 of sublingual grass pollen tablets as
pharmaceutical specialties. New applications are being pur-
sued, encompassing the development of sublingual tablets
for mite and ragweed pollen allergies, as well as the evalua-
tion of SLIT as a treatment of asthma. Additional frontiers
to explore in the long term include the development of
sublingual vaccines for food allergies and atopic dermatitis.
In parallel, second-generation vaccines based on recom-
binant allergens are being investigated to treat birch pollen
allergies. These vaccines will associate recombinant allergens
in a native conformation, together with Th1/T Reg adjuvants6 Clinical and Developmental Immunology
and/or mucoadhesive particulate vector systems. If suc-
cessful, such recombinant sublingual vaccines could enhance
clinical eﬃcacy while reducing treatment duration and de-
creasing the dose of allergen administered.
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